SEARCH

SEARCH BY CITATION

References

  • 1
    Walboomers JMM,Jacobs MV,Manos MM,Bosch FX,Kummer A,Shah KV,Snijders PJF. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 2
    Muñoz N,Castellsague X,de Gonzalez AB,Gissman L. HPV in the etiology of human cancer. Vaccine 2006; 24: S1S10.
  • 3
    Handsfield HH. Clinical presentation and natural course of anogenital warts. Am J Med 1997; 102: 1620.
  • 4
    Parkin DM,Whelan SL,Ferlay J,Teppo L,Thomas DB. Cancer incidence in 5 continents, vol. 8 (IARC Scientific Publication No. 155). Lyon, France: International Agency for Research on Cancer (IARC), 2002.
  • 5
    Parkin DM,Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24( Suppl 3): S11S25.
  • 6
    Ferlay J,Bray F,Pisani P,Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, Version 2.0, IARC Press. Available at: www.depdb.iarc.fr/globocan/GLOBOCAN2002.HTM (accessed March 15, 2005).
  • 7
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 8
    Munoz N,Mendez F,Posso H,Molano M,van den Brule AJ,Ronderos M,Meijer C,Munoz A; Instituto Nacional de Cancerologia HPV study group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 15: 207787.
  • 9
    Lazcano-Ponce E,Herrero R,Muñoz N,Cruz A,Shah KV,Alonso P,Hernández P. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 41220.
  • 10
    Molano M,Posso H,Weiderpass E,van den Brule AJC,Ronderos M,Franceschi S,Meijer CJLM,Arslan A,Munoz N. Prevalence and determinants of HPV infection among colombian women with normal cytology. Br J Cancer 2002; 87: 32433.
  • 11
    Ferreccio C,Bratti MC,Sherman ME,Herrero R,Wacholder S,Hildesheim A,Burk RD,Hutchinson M,Alfaro M,Greenberg MD,Morales J,Rodriguez AC, et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 81523.
  • 12
    Matos E,Loria D,Amestoy GM,Herrera L,Prince MA,Moreno J,Krunfly C,van den Brule AJ,Meijer CJ,Munoz N,Herrero R. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003; 30: 5939.
  • 13
    Franco EL,Villa LL,Sobrinho JP,Prado JM,Rousseau MC,Desy M,Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 141523.
  • 14
    de Sanjose S,Almirall R,Lloveras B,Font R,Diaz M,Muñoz N,Català I,Meijer CJ,Snijders PJ,Herrero R,Bosch FX. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003; 30: 78893.
  • 15
    Gonzalez C,Ortiz M,Canals J,Munoz L,Jarrin I,de la Hera MG,Garcia-Saiz A,Del Amo J. Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain. Sex Transm Infect 2006; 82: 2602.
  • 16
    Castellsague X,Diaz M,de Sanjose S,Muñoz N,Herrero R,Franceschi S,Peeling RW,Ashley R,Smith JS,Snidjers PJF,Meijer CJ,Bosch FX. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 30314.
  • 17
    Muñoz N,Bosch FX,Castellsague X,Diaz M,de Sanjose S,Hammouda D,Shah KV,Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2006; 111: 27885.
  • 18
    Koshiol JE,Laurent SA,Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31: 74852.
  • 19
    Clarke P,Ebel C,Catotti DN,Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996; 7: 197200.
  • 20
    Longatto-Filho A,Erzen M,Branca M,Roteli-Martins C,Naud P,Derchain SF,Hammes L,Sarian LO,Braganca JF,Matos J,Gontijo R,Lima T, et al. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study. Int J Gynecol Cancer 2006; 16: 95562.
  • 21
    Garland SM,Hernandez-Avila M,Wheeler CM,Perez G,Harper DM,Leodolter S,Tang GWK,Ferris DG,Steben M,Bryan JT,Taddeo FJ,Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 192843.
  • 22
    The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 191527.
  • 23
    Olsson S-E,Villa LL,Costa R,Petta C,Andrade R,Malm C,Iversen O-E,Hoye J,Steinwall M,Riis-Johannessen G,Andersson-Ellstrom A,Elfgren K, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 2007; 25: 49319.
  • 24
    Villa LL,Costa RLR,Petta CA,Andrade RP,Paavonen J,Iversen O-E,Olsson S-E,Hoye J,Steinwall M,Riis-Johannessen G,Anderson-Ellstrom A,Elfgren K, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 145966.
  • 25
    Villa LL,Costa RLR,Petta CA,Andrade RP,Ault KA,Giuliano AR,Wheeler CM,Koutsky LA,Malm C,Lehtinen M,Skjeldestad FE,Olsson S-E, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 26
    Block SL,Nolan T,Sattler C,Barr E,Giacoletti KE,Marchant CD,Castellsague X,Rusche SA,Lukac S,Bryan JT,Cavanaugh PF,Jr,Reisinger KS. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 213545.
  • 27
    Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti K, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus (HPV) 6, 11, 16, 18 L1 virus-like-particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26: 201209.
  • 28
    Lowe RS,Brown DR,Bryan JT,Cook JC,George HA,Hofmann KJ,Hurni WM. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176: 11415.
  • 29
    Koutsky LA,Ault KA,Wheeler CM,Brown DR,Barr E,Alvarez FB,Chiacchierine LM,Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 164551.
  • 30
    Ault K,Giuliano AR,Edwards R,Tamms G,Kim L-L,Smith JF,Jansen KU,Allende M,Taddeo F,Shulsky D,Barr E. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22: 30047.
  • 31
    Opalka D,Lachman CE,MacMullen SA,Jansen KU,Smith JF,Chirmule N,Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10: 10815.
  • 32
    Howe SL,Vargas DE,Granada D,Smith JK. Cervical cancer prevention in remote rural Nicaragua: a program evaluation. Gynecol Oncol 2005; 99: S232S235.
  • 33
    Sarian LO,Derchain SF,Naud P,Roteli-Martins C,Longatto-Filho A,Tatti S,Branca M,Erzen M,Serpa-Hammes L,Matos J,Gontijo R,Braganca JF, et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen 2005; 12: 1429.
  • 34
    Syrjanen K,Naud P,Derchain S,Roteli-Martins C,Longatto-Filho A,Tatti S,Branca M,Erzen M,Hammes LS,Matos J,Gontijo R,Sarian L, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. Anticancer Res 2005; 25: 346980.